Analysts Set DexCom, Inc. (NASDAQ:DXCM) PT at $85.18

DexCom's continuous glucose monitoring systems continue to gain traction among analysts.

Mar. 12, 2026 at 6:24am

Got story updates? Submit your updates here. ›

DexCom, Inc. (NASDAQ:DXCM) has received an average recommendation of 'Moderate Buy' from the twenty-five research firms that are covering the firm, Marketbeat Ratings reports. The average 12-month price target among brokers that have covered the stock in the last year is $85.50.

Why it matters

DexCom is a leading medical device company in the continuous glucose monitoring (CGM) space, which is a rapidly growing market as more people with diabetes seek advanced tools to manage their condition. Analyst sentiment and price targets can provide insight into the company's performance and future growth potential.

The details

The analysts' recommendations and price targets for DexCom stock are based on the company's recent financial results and outlook. DexCom reported Q4 2025 revenue of $1.26 billion, up 13.1% year-over-year, and earnings per share of $0.68, exceeding analysts' expectations. The company's CGM systems have been gaining traction as they provide real-time glucose data, trend information, and alerts to help patients and clinicians better manage diabetes.

  • DexCom reported Q4 2025 results on February 12, 2026.
  • Analysts updated their price targets and recommendations in the days following the earnings release.

The players

DexCom, Inc.

A medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes.

Marketbeat Ratings

A research firm that tracks and reports on analyst recommendations and price targets for publicly traded companies.

Got photos? Submit your photos here. ›

The takeaway

DexCom's continuous glucose monitoring systems continue to gain traction among analysts, who see the company's products as valuable tools for diabetes management. The average price target of $85.50 suggests analysts believe DexCom stock has room for further upside as the CGM market expands.